New Pathways for Parkinson's Disease
NeuroTrials Research is conducting a research study on the safety of a new study drug for Parkinson’s disease and patients with mild cognitive impairment (MCI). This non-motor symptom occurs in about 30% of people with Parkinson's. Those with MCI may complain of feeling distracted or forgetful, or losing their train of thought in conversation.
All study-related care & study drug will be provided at no cost, & qualified participants will receive compensation for time & travel.
You may qualify if you:
For more information, call 404-851-9934 or complete the form below.